Drug Profile
Research programme: anti-CD4 positive T cell imaging - ImaginAb/Novotectid
Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator ImaginAb Inc; Novotectid
- Developer ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Crohn's-disease(Diagnosis) in USA (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis(Diagnosis) in USA (Parenteral)